This implies that passive immunization with tau antibodies is actually a viable therapeutic target and the CSF degree of p-tau262/356 or in the microtubule binding area (MTBD) can function a useful biomarker of tau pathology to observe tau therapeutics in clinical trials.A number of colleagues have built the counterargument the sensor mobile respon